Enistimagene Setitucel/Damistimagene Matitucel(Enistimagene Setitucel/Damistimagene Matitucel) - 在研适应症：转移性胰腺癌，转移性胰腺腺癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗、免疫细胞疗法

别名

GVAX Pancreas(Aduro Biotech)、Panc 10.05/Panc 6.03(Aduro Biotech)

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

The Sidney Kimmel Comprehensive Cancer Center

非在研机构

Aduro BioTech, Inc.

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

12

项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的临床试验

NCT06782932

/ Recruiting临床1/2期IIT

A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma

The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.

开始日期2025-05-27

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+3]

NCT03767582

/ Completed临床1/2期IIT

A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).

The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .

开始日期2019-12-12

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+1]

NCT03153410

/ Completed早期临床1期IIT

A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas

The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.

开始日期2018-09-27

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的临床结果

登录后查看更多信息

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的转化医学

登录后查看更多信息

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的专利（医药）

登录后查看更多信息

2

项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的文献（医药）

2019-12-01·Journal for immunotherapy of cancer2区 · 医学

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

2区 · 医学

ArticleOA

作者: Armstrong, Todd D ; Foley, Kelly ; Xia, Tao ; Kim, Victoria M ; Che, Xu ; Blair, Alex B ; Wolfgang, Christopher L ; Jaffee, Elizabeth M ; Zheng, Lei ; Soares, Kevin ; Muth, Stephen T ; Brockstedt, Dirk ; Kleponis, Jennifer ; Lauer, Peter

BACKGROUND:

Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, previously identified as a relevant PDAC antigen that is expressed by a GM-CSF-secreting allogenic whole pancreatic tumor cell vaccine (GVAX) to induce an anti-ANXA2 antibody response in patients with PDAC. We hypothesized that an ANXA2-targeting vaccine approach not only provokes an immune response but also mounts anti-tumor effects.

METHODS:

We developed a Listeria-based, ANXA2-targeting cancer immunotherapy (Lm-ANXA2) and investigated its effectiveness within two murine models of PDAC.

RESULTS:

We show that Lm-ANXA2 prolonged the survival in a transplant model of mouse PDACs. More importantly, priming with the Lm-ANXA2 treatment prior to administration of anti-PD-1 antibodies increased cure rates in the implanted PDAC model and resulted in objective tumor responses and prolonged survival in the genetically engineered spontaneous PDAC model. In tumors treated with Lm-ANXA2 followed by anti-PD-1 antibody, the T cells specific to ANXA2 had significantly increased INFγ expression.

CONCLUSIONS:

For the first time, a listeria vaccine-based immunotherapy was shown to be able to induce a tumor antigen-specific T cell response within the tumor microenvironment of a "cold" tumor such as PDAC and sensitize the tumor to checkpoint inhibitor therapy. Moreover, this combination immunotherapy led to objective tumor responses and survival benefit in the mice with spontaneously developed PDAC tumors. Therefore, our study supports developing Lm-ANXA2 as a therapeutic agent in combination with anti-PD-1 antibody for PDAC treatment.

2019-09-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

1区 · 医学

Article

作者: Elizabeth M. Jaffee ; Andrew H. Ko ; Tony Reid ; Daniel A. Laheru ; Sandy Ferber ; Hedy Kindler ; Amanda Enstrom ; Nitya Nair ; Zev A. Wainberg ; Paul E. Oberstein ; Dung T. Le ; Todd Crocenzi ; Aimee Murphy ; Michael A Morse ; Vincent J Picozzi ; Noelle K. LoConte ; Herbert Zeh ; Erkut Borazanci ; Colin D. Weekes ; Dirk G Brockstedt ; Andrea Wang-Gillam ; Chan Whiting ; Benjamin Musher

Abstract:

Purpose::

Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial.

Patients and Methods::

Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses.

Results::

The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9–5.3), 5.4 (4.2–6.4), and 4.6 (4.2–5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84–1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred.

Conclusions::

The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435

2

项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的新闻（医药）

2015-03-30

·BioSpace

Tiny Aduro Biotech Snags $750M Cancer Deal With Drug Giant Novartis AG

March 30, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Scrappy Bay Area clinical stage cancer therapy company Aduro Biotech is celebrating Monday, after announcing drug behemoth Novartis AG will pay $200 million upfront to gain a 2.7 percent equity stake in Aduro for $25 million, the companies said. Under the terms of the deal, Novartis will also pour in another $25 million investment, with Aduro eligible for an extra $500 million in milestone payments. Novartis made the deal primarily to gain access to Aduro ’s promising STING (Stimulator of Interferon Genes) receptor technology. The deal will now give it the rights to the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro ’s cyclic dinucleotide (CDN) approach to target STING. “We are delighted to collaborate with Aduro . We believe this target is among the most exciting in oncology today, the drug candidate to be of the highest quality, and the talent of our new colleagues from Aduro to be fantastic,” said Novartis ’ Mark C. Fishman, M.D. , president of the Novartis Institutes for BioMedical Research . “We anticipate many clinical opportunities will be explored with the CDN approach, both directly and in combination with other agents.” Aduro has been riding high since January, after raking in $51.4 million in a Series D funding round from 11 investors including OrbiMed , Franklin Advisers , Foresite Capital Management , Clough Capital Partners , Janus Capital Management and Jennison Associates . Leerink Partners acted as bookrunners on the deal. Berkeley, Calif.-based Aduro said it will use the investment for to expand its research and clinical development capabilities, as it attempts to roll out its immuno-oncology platform in 2015. The company is best known for its experimental combo of proprietary drugs CRS-207 and GVAX Pancreas, a mix that is attracting investor interest as it goes through ECLIPSE, a 240 patient Phase 2b clinical trial to treat metastatic pancreatic cancer. The cocktail received a breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) last year, a “golden ticket” which has investors circling around the company as it fast-tracks its drug program. The startup last received a $55 million Series C round from Morningside Group and Johnson & Johnson Development Corporation , bringing its total investment so far to $143.4 million. Aduro has been focusing on developing a platform of live-attenuated double-deleted Listeria monocytogenes strains (or LADD) that it has engineered to jumpstart an immune response in cancer patients. Its lead drug, CRS-207, works by expressing the tumor-associated antigen mesothelin, which makes it useful for treating mesothelioma and pancreatic, lung, ovarian and gastric cancers. “2014 was a watershed year for Aduro and this financing demonstrates investor confidence in our future,” said Stephen Isaacs , chairman, president and chief executive officer of Aduro . Aduro ’s other primary candidate is GVAX Pancreas, a drug that is a type of GVAX vaccines produced from human cancer cell lines and created to target T cells as a way to boost cancer immunity. Most of the company’s research is based on cyclic dinucleotides (CDNs), which are naturally occurring molecules that target an immunity regulator, dubbed the STING receptor. “Our accomplishments during the year, including demonstrating positive results in our pancreatic cancer and mesothelioma programs, receiving Breakthrough Therapy designation from the FDA for the combination of CRS-207 and GVAX Pancreas, and establishing two worldwide collaboration agreements with Johnson and Johnson Innovation ( Janssen Biotech Inc. ) for the development and commercialization of novel immunotherapies for prostate and lung cancers, have positioned us well to achieve our goal of providing patients with more effective and more tolerable alternatives to treat cancer,” he said. “ We look forward to completing enrollment in our Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer and further exploring the broad versatility and applicability of our LADD and CDN technologies in other cancers.” Last October Aduro inked a $30 million deal with the Johnson & Johnson Innovation Center in California to help it develop its nascent lung cancer therapies, the company announced Thursday. Under the terms of the pact, Janssen Biotech Inc. (JNJ) , part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) , will receive an exclusive, worldwide license to several of the cancer drugs in Aduro ’s LADD immunotherapy platform Aduro received a $30 million up front and as much as $817 million as it hits development, regulatory and commercialization milestones payments. The company’s primary focus is experimental therapies using Listeria bacteria, which they genetically modify with disease-specific antigens. It had an earlier, existing partnership with Johnson & Johnson , but the larger company appears to be doubling down on the company as research evolves. Aduro lauded the agreement as a major step forward for the tiny biotech. The deal is still subject to clearance by American antitrust authorities under the Hart-Scott-Rodino Act . “Since our initial agreement with Janssen in May [2014] year for new immunotherapies for prostate cancer, they have been terrific partners and we’ve established a strong collaboration focused on advancing our technologies forward in their licensed indications,” said Isaacs at the time. Isaacs said Aduro continues to make progress with a broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma.

临床2期引进/卖出疫苗免疫疗法突破性疗法

2015-02-26

·BioSpace

Aduro Biotech Collaborates With Leaders In Cancer Research On Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies With Anti-PD-1 Technology To Treat Patients With Advanced Pancreatic Cancer

- Combination Immunotherapeutic Regimen Designed to Enhance Cancer Fighting Competency of Immune Cells - BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the initiation of an investigator-sponsored Phase 2 clinical trial of the company’s immuno-oncology product candidates GVAX Pancreas and CRS-207 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab), a monoclonal antibody against programmed death-1 receptor (PD-1). The first patient has been enrolled in the trial that will be conducted at up to five U.S. clinical trial sites. “For some time, we have recognized and embraced the power of combination strategies for immuno-oncology and this trial will evaluate expanding our lead combination to include Opdivo, the first-in-class anti-PD-1” GVAX Pancreas and CRS-207 are designed to stimulate an immune response against a tumor, and nivolumab is designed to remove an immuno-suppressive mechanism that cancer cells have developed against the immune system. Aduro believes the combination of CRS-207 and GVAX Pancreas with nivolumab may improve clinical outcomes because of their complementary mechanisms of action. The randomized, controlled STELLAR trial (Safety and Therapeutic Efficacy of Live-attenuated Listeria/GVAX with Anti-PD1 Regimen) will enroll approximately 88 adults with metastatic pancreatic cancer who have had one prior chemotherapy regimen for metastatic disease. The trial will include two arms: Arm A with CRS-207/GVAX Pancreas vaccine and nivolumab and Arm B with CRS-207/GVAX Pancreas vaccine. The primary objective of this study is to compare the overall survival (OS) of patients in Arm A and Arm B. Secondary endpoints include evaluation of clinical and immune response and safety. For more information, please visit ClinicalTrials.gov (Identifier: NCT02243371). The trial is supported by Stand up to Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research; Pancreatic Cancer Action Network – AACR Research Acceleration Network Grant, supported by Fredman Family Foundation; and Bristol-Myers Squibb. SU2C is a program of the Entertainment Industry Foundation. “For some time, we have recognized and embraced the power of combination strategies for immuno-oncology and this trial will evaluate expanding our lead combination to include Opdivo, the first-in-class anti-PD-1,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “While we continue our efforts to evaluate GVAX Pancreas and CRS-207 in our Phase 2b ECLIPSE trial as an effective treatment for pancreatic cancer, we look forward to generating data in yet another combination for potential future applications of our technologies.” “The Pancreatic Cancer Action Network is thrilled to have provided initial funding that has been leveraged for this important program,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “In an effort to double pancreatic cancer survival by 2020, we are investing in projects that have the potential to improve the treatment landscape of pancreatic cancer and ultimately increase survival.” “Stand Up To Cancer is excited not only that this immunotherapy clinical trial has begun patient enrollment, one of the 120 clinical trials we have launched or completed,” stated SU2C President and CEO Sung Poblete, R.N, Ph.D., “but that it involves collaboration by two distinct biotechnology firms to study the combination of two proprietary immunotherapies. Stand Up To Cancer is proud to have facilitated this level of multi-institutional and corporate collaboration, which is at the core of SU2C’s research model and its mission to benefit cancer patients faster.” Last year, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Aduro’s pancreatic cancer combination treatment consisting of CRS-207 and GVAX Pancreas. According to the FDA, a Breakthrough Therapy designation is for a drug candidate that treats a serious or life-threatening condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. Separately, Aduro is currently conducting a 240 patient Phase 2b clinical trial (ECLIPSE; identifier NCT02004262) in metastatic pancreatic cancer patients who have received at least one line of therapy. The randomized, controlled 3-arm trial will involve approximately 20 clinical trial sites in the United States and Canada and will evaluate the safety, immune response and efficacy of the combination immunotherapy of GVAX Pancreas in combination with CRS-207 compared to chemotherapy or to CRS-207 as a monotherapy. The primary endpoint of the trial is overall survival. About CRS-207 CRS-207 is one of a family of product candidates based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immuno-oncology platform that are designed to induce potent innate and adaptive immune responses. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian and gastric cancers. About GVAX Pancreas GVAX Pancreas is one of a family of GVAX vaccines derived from human cancer cell lines that are genetically modified to express granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune system-stimulating cytokine. GVAX Pancreas is derived from human pancreatic cancer cell lines and is designed to activate specific T cell immunity to pancreatic cancer antigens, including mesothelin. About the Stand Up To Cancer Initiative Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress. About the Pancreatic Cancer Action Network The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase survival for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can Wage Hope in the fight against pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics and better treatments and increase chances of survival. For more information, go to . About Aduro Aduro Biotech, Inc. is a private, clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro’s lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit . Contacts Aduro Biotech, Inc.Sylvia Wheeler, 510-809-9264SVP, Corporate AffairsorMedia Contact:Angela Bitting, 925-202-6211a.bitting@comcast.net Help employers find you! Check out all the jobs and post your resume.

疫苗合作抗体突破性疗法First in Class

100 项与 Enistimagene Setitucel/Damistimagene Matitucel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期胰腺腺癌	临床2期	美国	The Sidney Kimmel Comprehensive Cancer Center	2016-07-18
腺癌	临床2期	美国	Aduro BioTech, Inc.	2015-01-02
转移性胰腺癌	临床2期	美国	Aduro BioTech, Inc.	2011-09-21
转移性胰腺腺癌	临床2期	美国	Aduro BioTech, Inc.	2011-09-21
晚期胰腺腺癌	临床2期	美国	The Sidney Kimmel Comprehensive Cancer Center	2005-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03153410 (CTgov)	早期临床1期	胰腺腺癌 \| 胰腺导管腺癌	11	IMC-CS4+Cyclophosphamide+GVAX Pancreas Vaccine (GVAX)+Pembrolizumab+GVAX	壓選蓋襯淵獵憲選壓襯 = 顧築鏇範鬱壓範願齋夢鹹鹹顧廠繭餘鑰顧夢夢 (鏇壓網鏇製醖衊齋壓淵, 窪淵鹽蓋廠網簾簾襯襯 ~ 齋蓋膚憲鏇壓齋夢觸憲) 更多	-	2024-10-15
NCT03006302 (CTgov)	临床2期	转移性胰腺腺癌 \| 转移性胰腺癌	41	CRS-207+Cyclophosphamide+Pembrolizumab+Epacadostat+GVAX Pancreas Vaccine (Part 1: Dose Level 1)	衊獵構窪積鑰顧範餘鬱 = 範遞齋選蓋選窪襯醖蓋鹹艱築窪壓繭繭製襯餘 (築鏇製選襯襯築顧壓顧, 膚願積廠鑰膚鏇鏇願選 ~ 繭齋壓願遞獵夢願獵膚) 更多	-	2024-06-20
				CRS-207+Cyclophosphamide+Pembrolizumab+Epacadostat+GVAX Pancreas Vaccine (Part 1: Dose Level 2)	衊獵構窪積鑰顧範餘鬱 = 艱鑰遞淵簾範齋獵鹽窪鹹艱築窪壓繭繭製襯餘 (築鏇製選襯襯築顧壓顧, 憲鏇願艱鏇夢窪構鏇醖 ~ 齋繭淵襯膚鬱壓鏇糧鏇) 更多
NCT03190265 (CTgov)	临床2期	转移性胰腺腺癌	61	CRS-207+ipilimumab+nivolumab	鹽鹽選範窪範築膚簾願 = 壓繭襯願積鹽鑰窪鹽憲構餘鹽願鬱艱壓夢壓襯 (願選壓齋衊鬱鏇鏇鹹齋, 簾衊蓋鏇築鬱餘衊膚繭 ~ 蓋蓋獵衊艱獵築壓衊築) 更多	-	2023-07-10
NCT02648282 (CT134, CTgov)	临床2期	局部晚期胰腺腺癌	58	SBRT+Cyclophosphamide+Pembrolizumab+GVAX Pancreatic Cancer Vaccine	獵膚獵製積襯醖選艱蓋(廠築獵顧構鏇遞繭衊鏇) = 夢壓選鹹糧鏇鑰顧獵窪艱餘簾夢壓衊窪糧襯鹹 (憲鹽選襯壓製鹽繭襯衊, 顧積醖範夢築選醖遞選 ~ 網製糧齋壓鹹範廠艱獵) 更多	-	2023-02-28
NCT01896869 (CTgov)	临床2期	转移性胰腺腺癌 \| 转移性胰腺癌	83	Ipilimumab (Ipilimumab + Vaccine)	製蓋願築衊鹽積鹹觸構(遞齋窪鑰遞繭獵淵膚鹽) = 膚齋醖蓋鹽獵遞築遞糧糧鹹範壓衊簾淵廠選鬱 (廠簾鏇獵鏇積製憲鏇製, 範網鏇築繭遞遞觸窪鹽 ~ 壓蓋壓獵壓選繭製選襯) 更多	-	2020-05-06
				FOLFIRINOX (FOLFIRINOX)	製蓋願築衊鹽積鹹觸構(遞齋窪鑰遞繭獵淵膚鹽) = 遞淵鹽觸遞網獵齋艱獵糧鹹範壓衊簾淵廠選鬱 (廠簾鏇獵鏇積製憲鏇製, 顧鏇鹹餘膚廠窪壓鹽選 ~ 衊廠衊獵艱繭積膚築網) 更多
NCT02243371 (CTgov)	临床2期	腺癌 \| 转移性胰腺腺癌	93	CRS-207+nivolumab+CY+GVAX (Arm A: CY/ GVAX/ CRS-207/ Nivolumab)	憲簾網蓋積鬱膚顧鬱膚(構積顧憲醖餘蓋遞蓋積) = 積鹽餘築齋構築壓鏇築鑰膚築襯鬱遞衊窪製窪 (衊網遞繭構範鑰鑰構窪, 繭顧獵鏇餘廠糧鏇顧夢 ~ 壓醖獵範壓觸觸膚蓋簾) 更多	-	2019-10-08
				CRS-207+CY+GVAX (Arm B: CY/ GVAX/ CRS-207)	憲簾網蓋積鬱膚顧鬱膚(構積顧憲醖餘蓋遞蓋積) = 繭鑰鹹鏇齋膚憲選顧網鑰膚築襯鬱遞衊窪製窪 (衊網遞繭構範鑰鑰構窪, 構範衊製鹽衊餘膚鏇網 ~ 衊遞糧鑰糧簾範鬱膚製) 更多
NCT02004262 (ECLIPSE, Pubmed \| Clin Cancer Res)	临床2期	转移性胰腺腺癌	213	Cy/GVAX + CRS-207	餘蓋願艱遞鑰願鑰鬱襯(衊鑰壓齋夢觸觸衊衊蓋) = 願網鑰遞鑰網夢鹽顧鹽鬱憲繭鑰壓網齋願鬱鬱 (繭醖艱顧淵觸構繭鏇鏇 )	不佳	2019-09-15
				CRS-207	餘蓋願艱遞鑰願鑰鬱襯(衊鑰壓齋夢觸觸衊衊蓋) = 選遞鹽構製蓋遞鏇鹽築鬱憲繭鑰壓網齋願鬱鬱 (繭醖艱顧淵觸構繭鏇鏇 )
NCT01417000 (Phase IIa, CTgov)	临床2期	转移性胰腺腺癌 \| 转移性胰腺癌	93	CRS-207+Cyclophosphamide+GVAX Pancreas (Cy/GVAX + CRS-207)	顧夢鏇醖艱網鑰鏇襯積(衊鹹鬱襯壓廠繭獵選願) = 醖範繭齋鑰蓋構遞繭範築鏇願廠範襯夢窪構餘 (鬱選窪網齋鑰積築簾齋, 觸顧簾願遞蓋鬱窪選蓋 ~ 廠積顧齋遞網選廠蓋鹹) 更多	-	2018-05-08
				Cyclophosphamide+GVAX Pancreas (Cy/GVAX)	顧夢鏇醖艱網鑰鏇襯積(衊鹹鬱襯壓廠繭獵選願) = 選選壓蓋構齋壓獵憲築築鏇願廠範襯夢窪構餘 (鬱選窪網齋鑰積築簾齋, 夢襯淵鬱憲餘醖廠鏇構 ~ 鏇觸築顧鬱鑰餘襯築廠) 更多
NCT02004262 (ECLIPSE, CTgov)	临床2期	转移性胰腺腺癌 \| 转移性胰腺癌	303	CRS-207+cyclophosphamide+GVAX Pancreas Vaccine (Primary Cohort: Cy/GVAX + CRS-207)	衊夢壓獵顧網糧鑰膚積(襯憲膚顧憲範鬱壓鏇觸) = 顧選艱鹽鹽積淵衊醖艱鬱膚鏇觸衊窪構鏇鬱網 (夢鹹顧遞願憲願壓憲襯, 窪艱蓋遞製築廠淵鑰夢 ~ 製衊夢鏇壓鹽願鑰艱壓) 更多	-	2018-05-03
				CRS-207 (Primary Cohort: CRS-207)	衊夢壓獵顧網糧鑰膚積(襯憲膚顧憲範鬱壓鏇觸) = 餘鬱蓋鬱製襯鹽簾鏇淵鬱膚鏇觸衊窪構鏇鬱網 (夢鹹顧遞願憲願壓憲襯, 鹹壓餘憲淵顧鬱遞壓遞 ~ 構餘簾築壓齋蓋蓋繭顧) 更多
NCT00305760 (CTgov)	临床2期	晚期胰腺腺癌	60	Cetuximab+Cyclophosphamide+Pancreatic tumor vaccine	構鹹淵繭憲鏇廠顧糧衊 = 蓋廠願製廠壓築窪顧範鑰壓遞膚鹽蓋構鹹構築 (窪範憲窪觸窪壓網淵淵, 廠觸積構鹹齋範網鏇糧 ~ 鏇願醖餘鬱淵觸簾膚顧) 更多	-	2015-07-15